Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 2, 2024Blood Cancer JournalOpen Access

Continuously improving outcome over time after second allogeneic stem cell transplantation in relapsed acute myeloid leukemia: an EBMT registry analysis of 1540 patients

View Full Paper
Ask AI
Bookmark
Share

Authors

ASAnn‐Kristin SchmälterUniversity of AugsburgMNMaud NgoyaSorbonne UniversitéJGJacques‐Emmanuel GalimardInserm

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Schmälter et al. (2024) studied this question.

synapsesocial.com/papers/6a1d98e8cc9f7df1b705ae41https://doi.org/10.1038/s41408-024-01060-4
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Clinical experience with the BCL 2‐inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies2017 · 445 citations
  2. 2Conditioning intensity in secondary AML with prior myelodysplastic syndrome/myeloproliferative disorders: an EBMT ALWP study2018 · 45 citations
  3. 3Durable Remissions with Ivosidenib in IDH1 -Mutated Relapsed or Refractory AML2018 · 1,473 citations
  4. 4Prediction of Response and Survival Following Treatment with Azacitidine for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes after Allogeneic Hematopoietic Stem Cell Transplantation2020 · 48 citations
  5. 5Second haploidentical stem cell transplantation (HAPLO-SCT2) after relapse from a first HAPLO-SCT in acute leukaemia—a study on behalf of the Acute Leukaemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)2023 · 10 citations